Immutep CMO reports initial share holdings
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Winckels Stephan Karel Gerard
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Performance rights (right to receive) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Performance rights (right to receive) — 665,124 contracts (Direct);
Ordinary Shares — 92,935 shares (Direct)
Footnotes (3)
- F1. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2026 and the vesting of the remaining 443,416 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
- F2. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2027 and the vesting of the remaining 221,708 performance rights is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
- F3. Granted on October 13, 2025. 221,708 performance rights will vest on December 1, 2028 and the vesting is dependent on Mr. Winckels achieving key performance indicators at the applicable vesting date.
Key Figures
Ordinary Shares held: 92,935 shares
Performance rights tranche 1: 221,708 underlying shares
Performance rights tranche 2: 221,708 underlying shares
+3 more
6 metrics
Ordinary Shares held
92,935 shares
Direct ownership following Form 3 report
Performance rights tranche 1
221,708 underlying shares
Vesting on December 1, 2026, exercise price $0.0000
Performance rights tranche 2
221,708 underlying shares
Vesting on December 1, 2027, exercise price $0.0000
Performance rights tranche 3
221,708 underlying shares
Vesting on December 1, 2028, exercise price $0.0000
Exercise price of performance rights
$0.0000 per share
Performance rights over Ordinary Shares
Performance rights expiration
October 13, 2030
Expiration date for all three performance-rights blocks
Key Terms
Performance rights (right to receive), Ordinary Shares, key performance indicators, Chief Medical Officer
4 terms
Performance rights (right to receive) financial
"security_title": "Performance rights (right to receive)""
key performance indicators financial
"vesting is dependent on Mr. Winckels achieving key performance indicators"
Key performance indicators are specific measurements used to track how well a person, team, or organization is achieving its goals. They act like report cards, providing clear signs of progress or areas needing improvement. For investors, KPIs help assess the health and future potential of a business by highlighting its most important strengths and challenges.
Chief Medical Officer financial
"officer_title": "Chief Medical Officer""
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position did IMMUTEP (IMMP) disclose for Stephan Winckels?
IMMUTEP disclosed that Chief Medical Officer Stephan Winckels directly holds 92,935 Ordinary Shares. He also holds three tranches of 221,708 performance rights over Ordinary Shares, each vesting between 2026 and 2028, subject to key performance indicators and expiring in 2030.
What are the vesting conditions for IMMUTEP performance rights held by the CMO?
The performance rights were granted on October 13, 2025 and vest on set dates if key performance indicators are met. One 221,708 block vests December 1, 2026, another on December 1, 2027, and another on December 1, 2028, with vesting explicitly tied to performance criteria.
What is the exercise price and expiry of IMMUTEP CMO performance rights?
Each block of performance rights over IMMUTEP Ordinary Shares carries an exercise price of $0.0000. According to the disclosure, these rights share an expiration date of October 13, 2030, meaning they must vest and be exercised, if eligible, before that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates